SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 1, 2021 | Post-IPO Equity | $375M | 11 | — | — | Detail |
Sep 1, 2021 | IPO | $630M | — | — | — | Detail |
Dec 23, 2020 | Series A | $81M | 11 | — | — | Detail |
Nov 25, 2020 | Series A | $121M | 11 | Casdin Capital | — | Detail |
Jan 3, 2018 | Series Unknown | $200M | 7 | iCarbonX | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
iCarbonX | Yes | Series Unknown |
dRx Capital | Yes | Series A |
ARK Investment Management | — | Post-IPO Equity |
Casdin Capital | — | Post-IPO Equity |
Corvex | — | Post-IPO Equity |
Counterpoint Global | — | Post-IPO Equity |
Farallon Capital Management | — | Post-IPO Equity |
Illumina | — | Post-IPO Equity |
Janus Henderson Investors | — | Post-IPO Equity |
Novartis Pharma | — | Post-IPO Equity |
SomaLogic has acquired 1 organizations. Their most recent acquisition was Palamedrix on Jul 26, 2022. They acquired Palamedrix for $35M.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jul 26, 2022
Palamedrix
|
Biotechnology | acquisition | $ 35M | Detail |